O.33Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study

Pasnoor, Mamatha; Bril, Vera; Levine, Todd; Trivedi, Jaya; Silvestri, Nicholas J.; Phadnis, Milind A.; Saperstein, David; Nations, Sharon P.; Katzberg, Hans D.; Wolfe, Gil I.; Herbelin, Laura; Higgs, Kiley; Heim, Albert; Statland, Jeffrey; Barohn, Richard J.; Dimachkie, Mazen M.

doi:10.1016/j.nmd.2019.06.316

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a mean follow-up period of about 7 months, all had stable or improved MGFA status, significant improvement in MG-ADL, MG-QOL and the visual analogue scale (VAS) for patient satisfaction ( 36 ). The efficacy, safety and tolerability of SCIG in 22 seropositive MG patients was assessed in a multicentre North American open label trial ( 37 ). After a 10 week screening period with periodic IVIG treatments, stable patients were transitioned to weekly SCIG for 12 weeks.…”

Section: Subcutaneous Immunoglobulin (Scig)mentioning

confidence: 99%

“…The study showed improved scores in the QMG, manual muscle testing (MMT), and MGC with high patient satisfaction and no serious adverse effects. The treatment success rate at 12 weeks was 85% (37,38). Thus SCIG offers a novel, efficacious and patient-friendly alternative to IVIG in maintenance therapy for MG, although it has not been tested for acute management of MG. Additionally, its corticosteroidsparing effects have not been established.…”

Section: Subcutaneous Immunoglobulin (Scig)mentioning

confidence: 99%

See 1 more Smart Citation

Novel Treatments in Myasthenia Gravis

2020

View full text Add to dashboard Cite

Myasthenia gravis (MG) is the prototypical autoimmune disorder caused by specific autoantibodies at the neuromuscular junction. Broad-based immunotherapies, such as corticosteroids, azathioprine, mycophenolate, tacrolimus, and cyclosporine, have been effective in controlling symptoms of myasthenia. While being effective in a majority of MG patients many of these immunosuppressive agents are associated with long-term side effects, often intolerable for patients, and take several months to be effective. With advances in translational research and drug development capabilities, more directed therapeutic agents that can alter the future of MG treatment have been developed. This review focuses on the aberrant immunological processes in MG, the novel agents that target them along with the clinical evidence for efficacy and safety. These agents include terminal complement C5 inhibitors, Fc receptor inhibitors, B cell depleting agents (anti CD 19 and 20 and B cell activating factor [BAFF)]inhibitors), proteosome inhibitors, T cells and cytokine based therapies (chimeric antigen receptor T [CART-T] cell therapy), autologous stem cell transplantation, and subcutaneous immunoglobulin (SCIG). Most of these new agents have advantages over conventional immunosuppressive treatment (IST) for MG therapy in terms of faster onset of action, favourable side effect profile and the potential for a sustained and long-term remission.

show abstract

Section: Subcutaneous Immunoglobulin (Scig)mentioning

confidence: 99%

Section: Subcutaneous Immunoglobulin (Scig)mentioning

confidence: 99%